Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 6/20 | 0.41 |
| ▸ | FNTB | P49356 | 6/20 | 0.41 |
| ▸ | PGGT1B | P53609 | 6/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL696754 | 0.92 | CYP19A1 (0.40) | FNTAFNTBPGGT1BMAOBCYP11B1 | |
| SCHEMBL698126 | 0.90 | GRIN2B (0.41) | TDP1RAB9AMAOBALDH1A1LMNA | |
| SCHEMBL3533515 | 0.89 | TP53 (0.40) | TDP1RAB9AALDH1A1LMNAHPGD | |
| SCHEMBL697760 | 0.89 | L3MBTL1 (0.38) | FNTAFNTBPGGT1BTDP1RAB9A | |
| SCHEMBL703335 | 0.88 | GRIN2B (0.42) | RAB9ALMNA | |
| SCHEMBL698919 | 0.88 | L3MBTL1 (0.38) | TDP1RAB9AMAOBALDH1A1LMNA | |
| SCHEMBL696991 | 0.88 | L3MBTL1 (0.40) | RAB9AMAOBLMNA | |
| SCHEMBL696660 | 0.88 | GRIN2B (0.38) | RAB9AMAOBLMNA | |
| SCHEMBL698246 | 0.87 | MAPT (0.44) | RAB9AMAOBLMNASMN1; SMN2 | |
| SCHEMBL696627 | 0.87 | GRIN2B (0.40) | TDP1RAB9AALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2423199-A1 | Substituted imidazoles and their use as pesticides | Pfizer Limited (GB) | 2012-02-29 | — | — | EP | disclosed |
| US-7825149-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2010-11-02 | — | — | US | disclosed |
| US-20090312326-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| US-7592362-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| US-7547718-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2009-06-16 | — | — | US | disclosed |
| US-7544706-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2009-06-09 | — | — | US | disclosed |
| US-20080125473-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2008-05-29 | — | — | US | disclosed |
| US-20080119536-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2008-05-22 | — | — | US | disclosed |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | PFIZER INC. (US) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125473-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | FNTA 1512/4885FNTB 1908/4885PGGT1B 146/4885 |
| US-20090312326-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | FNTA 1512/4885FNTB 1908/4885PGGT1B 146/4885 |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | FNTA 1512/4885FNTB 1908/4885PGGT1B 146/4885 |
| US-20080119536-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | FNTA 1512/4885FNTB 1908/4885PGGT1B 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.